news
Unpredicted binding found between SARS-CoV-2 and hepatitis C drug, telaprevir
Insights into the interaction between telaprevir and the SARS-CoV-2 main protease could aid in future COVID-19 drug design, say scientists.
List view / Grid view
Covid-19
news
Lung-on-a-chip models enable advanced study of immune response
Researchers have reviewed lung-on-a-chip technologies, finding they are useful for representing the various disease pathologies.
news
Molecular technique could provide key for SARS-CoV-2 drug discovery
Researchers are using a new method to isolate the complex between SARS-CoV-2 and the ACE2 receptor to keep it embedded in the cell membrane.
article
SARS-CoV-2 variants: the role of sequencing and vaccine development
Professor Martin Michaelis and Dr Mark Wass explain why new SARS-CoV-2 variants are emerging around the world and how vaccines will have to adapt in response.
news
Spike protein analysis explains faster spread of SARS-CoV-2 variants
Using cryo-electron microscopy, researchers have imaged how the SARS-CoV-2 Spike protein changes with the D614G mutation to enable faster spread of infection.
news
Study identifies potential drug target for treating COVID-19
Researchers have shown that the PLpro coronavirus enzyme presents a possible target in the fight against COVID-19.
news
Researchers gain insight into metabolic pathways hijacked by SARS-CoV-2
SARS-CoV-2 diverts building blocks from glucose production to the assembly of purine bases, researchers have found.
news
Antibodies from COVID-19 vaccines less effective against SARS-CoV-2 variants
Researchers have shown antibodies induced by the Pfizer and Moderna vaccines are less effective at neutralising certain SARS-CoV-2 variants.
news
Mosquito protein could hold key to therapeutics against flaviviruses
A study has shown the mosquito protein AEG12 inhibits flaviviruses, the family of viruses that cause yellow fever, dengue and Zika.
news
Antisense oligonucleotide with potential to combat COVID-19 developed
Scientists have designed a compound named ASO-1 that could help to reduce immune response overactivation in patients with COVID-19.
article
What we know about COVID-19 and the inflammatory response
A year on from discovering COVID-19 we are starting to understand why some people suffer more severely after infection. Sadya Arnett discusses recent research into the interconnection between host inflammation and SARS-CoV-2.
news
High-CBD cannabis extracts could provide COVID-19 treatment
Cannabidiol's (CBD) anti-inflammatory properties could be harnessed to treat or prevent COVID-19, according to a new study.
news
SARS-CoV-2 mAb cocktail effective against all known variants of virus
A monoclonal antibody (mAb) cocktail, that targets sites on the Spike protein other than the E484K residue, can neutralise SARS-CoV-2.
news
SARS-CoV-2 mutations complicate killer T cell immune response, study shows
Researchers have found that mutations in SARS-CoV-2 T cell epitopes enable the virus to evade the immune response of killer T cells.
news
Compounds that inhibit main protease of SARS-CoV-2 discovered
Using high-throughput screening techniques, researchers have identified two families of active substances that block SARS-CoV-2 replication.
